Company Profile

SeaChange Pharmaceuticals Inc
Profile last edited on: 7/14/19      CAGE: 5LPD7      UEI:

Business Identifier: Computational techniques to find new uses for established drugs
Year Founded
2009
First Award
2010
Latest Award
2014
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

409 Illinois Street
San Francisco, CA 94158
   (415) 937-1732
   info@seachangepharma.com
   www.seachangepharma.com
Location: Single
Congr. District: 12
County: San Francisco

Public Profile

Spun out of the University of California San Francisco (UCSF), SeaChange uses a novel computational technology, the similarity ensemble approach, to discover opportunities in off-target drug binding. The Similarity Ensemble Approach (SEA) is a new method to predict drug side effects and target opportunities. This technology is motivated by two ideas: that proteins can be related by the ligands that bind to them, and that one can exploit these relationships to discover new targets for established drugs. The company has used SEA to predict new targets for 22 marketed drugs against 32 targets; 25 of them were confirmed in experiments. Examples include the ß-blocking activity of Prozac and Paxil, consistent with two of the established, but unexplained, side effects of these drugs, the anti-serotonergic activity of Fabahistin, an anti-histamine now being advanced for Alzheimer’s, but whose primary targets are controversial, and the H4 histaminergic activity of the NNRTI AIDS drug Rescriptor. None of these off-target effects were previously known; all emerge quantitatively from the SEA calculation

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 2 NIH $1,102,137
Project Title: Drug Repurposing Using Pharmacological Networks
2013 1 NIH $301,225
Project Title: Relating Gpcrs By Biased Ligands For Enhanced Therapeutic Efficacy
2011 1 NIH $250,241
Project Title: Calculating Target Bias In Small Molecules For Library Design

Key People / Management

  Michael J Keiser -- President and Co-Founder

  Carl Nicholas Hodge -- Chief Scientific Officer

  John Irvin -- Founder & Scientific Advisor

  Brian Shoichet -- Scientific Advisor & Co-Founder